Search results
Showing 361 to 375 of 1688 results for carers
This guideline covers care and treatment for people with, or at risk of, chronic kidney disease (CKD). It aims to prevent or delay the progression, and reduce the risk of complications and cardiovascular disease. It also covers managing anaemia and hyperphosphataemia associated with CKD.
In development [GID-TA11156] Expected publication date: 14 January 2025
This quality standard covers preventing and controlling infection in adults, young people and children receiving healthcare in primary, community and secondary care settings. It includes preventing healthcare-associated infections that develop because of treatment or from being in a healthcare setting. It describes high-quality care in priority areas for improvement.
View quality statements for QS61Show all sections
Sections for QS61
- Quality statements
- Quality statement 1: Antimicrobial stewardship
- Quality statement 2: Organisational responsibility
- Quality statement 3: Hand decontamination
- Quality statement 4: Urinary catheters
- Quality statement 5: Vascular access devices
- Quality statement 6: Educating people about infection prevention and control
- Update information
Adrenal insufficiency: identification and management (NG243)
This guideline covers identifying and managing adrenal insufficiency (hypoadrenalism) in babies, children, young people and adults. It aims to improve the treatment of primary, secondary and tertiary adrenal insufficiency, and the prevention and management of adrenal crisis.
neurone disease (MND) on clinical practice, the person and their family and carers? Does repeated assessment provide more benefit than...
In development [GID-TA11376] Expected publication date: 25 June 2025
Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323]
In development [GID-TA11373] Expected publication date: TBC
Improving outcomes for people with brain and other central nervous system tumours (CSG10)
This guideline covers how healthcare services for people with brain tumours and other central nervous system tumours should be organised. It aims to improve care by recommending which healthcare professionals should be involved and the types of hospital or cancer centre best suited to provide the care.
In development [GID-TA11201] Expected publication date: 19 March 2025
In development [GID-TA11221] Expected publication date: 26 March 2025
This guideline covers helping adults and young people over 16 who are dependent on opioids to stop using drugs. It aims to reduce illicit drug use and improve people’s physical and mental health, relationships and employment.
Metastatic malignant disease of unknown primary origin in adults: diagnosis and management (CG104)
This guideline covers diagnosing and managing secondary cancer in people aged 18 and over when the site of the primary cancer is unknown. This includes people who have had treatment for cancer before. It aims to improve quality of life by offering advice on tests for identifying the site of the primary cancer and options for managing the person’s condition.
How voluntary and community sector (VCS) organisations can help us develop guidance
Support for organisations who contribute to developing our guidance
Evidence-based recommendations on sebelipase alfa (Kanuma) for long-term enzyme replacement therapy in Wolman disease (rapidly progressive lysosomal acid lipase deficiency) in people aged 2 years and under when treatment starts.
In development [GID-TA11203] Expected publication date: 05 March 2025